文献速递脑血管病

血糖状态分层的急性缺血性卒中患者72小时内双联抗血小板治疗的疗效与安全性

Efficacy and Safety of Dual Antiplatelet Treatment up to 72 Hours in Acute Ischemic Stroke Stratified by Glycemic Status.
PubMed 文献 · Ann Neurol · 2025-02-11

基于INSPIRES试验数据,按血糖状态分层分析氯吡格雷-阿司匹林与单用阿司匹林在轻型缺血性卒中或高危TIA患者中的疗效与安全性。共纳入6100例患者,无糖尿病和新诊断2型糖尿病者双联治疗降低复发卒中风险,有2型糖尿病病史者无显著获益,中重度出血无显著差异。

要点

  • 无2型糖尿病者:双联治疗复发卒中6.3% vs 单药8.4%,HR 0.75(95%CI 0.59-0.94;p=0.01)。
  • 新诊断2型糖尿病者:双联治疗复发卒中5.8% vs 单药13.0%,HR 0.30(95%CI 0.14-0.66;p=0.002)。
  • 有2型糖尿病病史者:双联治疗复发卒中10.0% vs 单药9.9%,HR 0.98(95%CI 0.72-1.33;p=0.88)。

核心结论

  • 在INSPIRES试验中,无2型糖尿病或新诊断2型糖尿病的轻型缺血性卒中或高危TIA患者从氯吡格雷-阿司匹林治疗中获益大于有2型糖尿病病史者。

研究设计与样本

  • 基于INSPIRES试验数据,将轻型缺血性卒中或高危TIA患者随机分配至氯吡格雷-阿司匹林组或单用阿司匹林组。
  • 共纳入6100例患者(每组3050例),中位年龄65岁(IQR 57-71),女性2185例(35.8%)。
  • 根据病史及住院期间临床医生诊断分为3个亚组:无2型糖尿病、新诊断2型糖尿病、有2型糖尿病病史。

主要发现

  • 无2型糖尿病者:双联治疗组复发卒中6.3% vs 单用阿司匹林组8.4%,HR 0.75(95%CI 0.59-0.94;p=0.01)。
  • 新诊断2型糖尿病者:双联治疗组复发卒中5.8% vs 单用阿司匹林组13.0%,HR 0.30(95%CI 0.14-0.66;p=0.002)。
  • 有2型糖尿病病史者:双联治疗组复发卒中10.0% vs 单用阿司匹林组9.9%,HR 0.98(95%CI 0.72-1.33;p=0.88),交互作用p=0.03。
  • 中重度出血事件在各血糖亚组间按治疗比较无显著差异。

临床怎么用

  • 作者认为,无2型糖尿病或新诊断2型糖尿病的轻型缺血性卒中或高危TIA患者从氯吡格雷-阿司匹林治疗中获益大于有2型糖尿病病史者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective was to investigate the efficacy and safety of clopidogrel-aspirin versus aspirin alone in patients after ischemic stroke by glycemic status using data from the Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial. METHODS: Patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) were randomized to clopidogrel-aspirin or aspirin alone. They were categorized into 3 subgroups according to glycemic status based on medical history and diagnosis by a clinician during hospitalization: without type 2 diabetes mellitus, with newly diagnosed type 2 diabetes, and with a history of type 2 diabetes mellitus. The primary efficacy and safety outcomes were new stroke and moderate-to-severe bleeding risk within 90-day follow-up. RESULTS: A total of 6,100 patients were enrolled (3,050 in each arm), with a median age of 65 years (interquartile range [IQR], 57-71) and 2,185 female (35.8%). Clopidogrel-aspirin treatment was associated with a reduction in recurrent stroke compared with aspirin alone in patients without type 2 diabetes mellitus (6.3% vs 8.4%; hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.59-0.94; p = 0.01) and those with newly diagnosed type 2 diabetes mellitus (5.8% vs 13.0%; HR, 0.30; 95% CI, 0.14-0.66; p = 0.002), but not in those with a history of type 2 diabetes mellitus (10.0% vs 9.9%; HR, 0.98; 95% CI, 0.72-1.33; p = 0.88) (p for interaction = 0.03). Moderate-to-severe bleeding events did not differ significantly by treatment across glycemic subgroups. INTERPRETATION: In the INSPIRES trial, patients without or with type 2 diabetes mellitus derived greater benefit from clopidogrel-aspirin than those with a history of type 2 diabetes mellitus after mild ischemic stroke or high-risk TIA. TRIAL REGISTRATION: INSPIRES, NCT03635749. Registered 15 August 2018, https://clinicaltrials.gov/search?cond=NCT03635749. ANN NEUROL 2025;98:174-182.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Zhou Q, Gao Y, Chen W, et al. Efficacy and Safety of Dual Antiplatelet Treatment up to 72 Hours in Acute Ischemic Stroke Stratified by Glycemic Status. Ann Neurol. 2025. PMID: 39931900. doi:10.1002/ana.27207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。